More Good News On Actemra In Severe COVID-19 – But Will Roche File For Approval?
Another Significant RECOVERY Result
Executive Summary
The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete its own studies.
You may also be interested in...
Novartis Q1 Preview: Profits Still Under Pressure From Lockdown
The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular.
Coronavirus Update: At One-Year Mark, WHO Stresses Importance Of Fair Vaccine Distribution
Plus Pfizer/BioNTech report real-world data from Israel on its vaccine, while Roche’s Actemra misses Phase III endpoint in another combo study with Veklury.
Tocilizumab COVID-19 Study Shows Bias Against Observational Studies, Harvard Prof Says
Study showing Roche’s Actemra decreased mortality in COVID-19 patients in ICUs by almost 10% was initially rejected by journal editors and then ignored by guideline writers and regulators. FDA officials and industry reps discuss what needs to be done to advance use of real-world evidence from observational studies.